Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Malignant hematopoietic cells of myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemias (CMML) and acute myeloid leukemias (AML) may be vulnerable to inhibition of poly(ADP ribose) polymerase 1/2 (PARP1/2) and apurinic/apyrimidinic endonuclease 1 (APE1). PARP1/2 and APE1 are critical enzym...

Full description

Bibliographic Details
Main Authors: Vanessa Kohl, Johanna Flach, Nicole Naumann, Susanne Brendel, Helga Kleiner, Christel Weiss, Wolfgang Seifarth, Daniel Nowak, Wolf-Karsten Hofmann, Alice Fabarius, Henning D. Popp
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
myelodysplastic syndrome
chronic myelomonocytic leukemia
acute myeloid leukemia
talazoparib
ape1 inhibitor iii
poly(adp ribose) polymerase 1/2
apurinic/apyrimidinic endonuclease 1
Online Access:https://www.mdpi.com/2072-6694/11/10/1493

Internet

https://www.mdpi.com/2072-6694/11/10/1493

Similar Items